Valuation: Evofem Biosciences, Inc.

Market Cap 1.06M 927K 855K 786K 1.49M 102M 1.51M 10.21M 4.01M 49.86M 3.98M 3.89M 172M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.48M 48.5M 44.74M 41.13M 77.93M 5.34B 79.27M 534M 210M 2.61B 208M 204M 8.99B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day-3.61%
1 week-15.79%
1 month+6.67%
3 months-10.11%
6 months-13.98%
Current year-15.79%
1 week 0.01
Extreme 0.0078
0.01
1 month 0.01
Extreme 0.0072
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.82
5 years 0
Extreme 0.0008
1,865.62
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/01/24Sell

Chief Financial Officer

104 0.0010%
21/12/23Sell

Director

10 0.0001%
13/04/23Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-3.61%-15.79%-13.98%-98.69% 1.06M
+0.35%-4.87%+49.87%+157.34% 1,031B
-2.69%-6.22%+59.19%+54.51% 595B
+0.44%-3.41%+30.97%+79.48% 431B
+0.98%-1.40%+29.49%+21.76% 326B
-0.34%-3.10%+27.00%+43.60% 277B
+1.63%-11.76%+19.72%+21.72% 263B
+3.39%+2.29%-23.68%-37.83% 224B
+0.86%-2.63%+22.50%+57.55% 193B
+1.28%-3.03%+20.76%+70.62% 164B
Average +0.23%-4.95%+22.18%+37.00% 350.43B
Weighted average by Cap. +0.21%-4.31%+35.59%+76.50%

Financials

2024 2025
Net sales 19.36M 16.93M 15.62M 14.36M 27.2M 1.86B 27.67M 186M 73.15M 911M 72.72M 71.12M 3.14B 20.18M 17.65M 16.28M 14.96M 28.35M 1.94B 28.84M 194M 76.25M 949M 75.8M 74.13M 3.27B
Net income -8.86M -7.75M -7.15M -6.57M -12.45M -853M -12.66M -85.31M -33.47M -417M -33.27M -32.54M -1.44B 391K 342K 315K 290K 549K 37.62M 559K 3.76M 1.48M 18.39M 1.47M 1.44M 63.38M
Net Debt 45.84M 40.08M 36.97M 33.99M 64.4M 4.41B 65.5M 441M 173M 2.16B 172M 168M 7.43B 54.42M 47.58M 43.89M 40.34M 76.44M 5.24B 77.75M 524M 206M 2.56B 204M 200M 8.82B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
15/07/26 $0.008000 -3.61% 7,780
14/07/26 $0.008300 -1.07% 241,142
13/07/26 $0.008390 -1.29% 9,821
10/07/26 $0.008500 -9.09% 317,881
09/07/26 $0.009350 -1.06% 41,324

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock